Tempus AI (NASDAQ:TEM) Price Target Raised to $66.00

Tempus AI (NASDAQ:TEM) had its price target upped by HC Wainwright from $56.00 to $66.00 in a report released on Friday, MarketBeat.com reports. The brokerage currently has a buy rating on the stock.

Several other equities research analysts also recently weighed in on TEM. Wall Street Zen raised Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Rothschild & Co Redburn started coverage on shares of Tempus AI in a report on Tuesday, September 8th. They set a “neutral” rating and a $67.00 price objective on the stock. Cantor Fitzgerald assumed coverage on shares of Tempus AI in a research report on Wednesday, September 2nd. They issued an “overweight” rating and a $80.00 price objective for the company. Guggenheim lifted their target price on shares of Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Finally, Freedom Capital raised shares of Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. Eleven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $69.33.

Tempus AI Stock Performance

Shares of NASDAQ:TEM opened at $59.01 on Friday. The firm has a 50 day moving average of $55.96 and a 200 day moving average of $52.30. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The company has a market capitalization of $10.65 billion, a price-to-earnings ratio of -40.98 and a beta of 3.72. Tempus AI has a 52 week low of $40.77 and a 52 week high of $104.32.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. During the same quarter last year, the firm earned ($0.22) EPS. The business’s revenue for the quarter was up 21.6% on a year-over-year basis. On average, sell-side analysts predict that Tempus AI will post -1.38 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Andrew Polovin sold 22,148 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the completion of the sale, the executive vice president owned 146,067 shares of the company’s stock, valued at $7,246,383.87. The trade was a 13.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 41,095 shares of Tempus AI stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total transaction of $2,038,722.95. Following the sale, the chief executive officer directly owned 562,463 shares in the company, valued at approximately $27,903,789.43. This trade represents a 6.81% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 1,043,988 shares of company stock valued at $56,963,417. Corporate insiders own 24.26% of the company’s stock.

Institutional Trading of Tempus AI

Large investors have recently made changes to their positions in the company. Victory Capital Management Inc. lifted its position in shares of Tempus AI by 1.5% during the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after purchasing an additional 162 shares during the last quarter. Truist Financial Corp grew its stake in Tempus AI by 5.8% in the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock worth $209,000 after purchasing an additional 194 shares in the last quarter. SeaCrest Wealth Management LLC increased its holdings in Tempus AI by 3.7% in the third quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company’s stock valued at $524,000 after buying an additional 229 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in Tempus AI by 64.5% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 653 shares of the company’s stock valued at $53,000 after buying an additional 256 shares during the last quarter. Finally, Pathstone Holdings LLC increased its holdings in Tempus AI by 1.4% in the third quarter. Pathstone Holdings LLC now owns 18,338 shares of the company’s stock valued at $1,480,000 after buying an additional 261 shares during the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: HC Wainwright raised its Tempus AI price target to $66 from $56 and maintained a “buy” rating, implying additional upside from recent trading levels and reinforcing bullish sentiment. Benzinga analyst coverage report
• Positive Sentiment: Tempus announced a plan to build a de-identified multimodal whole-genome dataset containing 100,000 genomes linked with longitudinal clinical data. The platform could strengthen the company’s data assets, improve AI research capabilities, and create opportunities for future pharmaceutical and healthcare partnerships. Tempus whole-genome dataset announcement
• Positive Sentiment: Tempus secured up to $9.5 million in ARPA-H funding to develop and deploy an autonomous AI agent for cardiology and heart-failure care. The award provides non-dilutive funding and validation from a U.S. government health research agency. Tempus ARPA-H award
• Positive Sentiment: ARPA-H selected six teams for a broader $62.7 million agentic cardiovascular AI program, highlighting growing public-sector investment in the market Tempus is targeting. ARPA-H cardiovascular AI program
• Neutral Sentiment: UBS, Roth Capital, and Rothschild & Co. Redburn initiated or announced coverage, but UBS reportedly assigned a neutral rating. The wider analyst attention may improve visibility while also signaling uncertainty about valuation and execution. UBS coverage of Tempus AI
• Negative Sentiment: The genomics platform and cardiovascular AI agent remain multi-year projects subject to funding milestones, clinical validation, regulatory approval, and commercialization risk. The government award is strategically positive but relatively modest compared with Tempus AI’s market value.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.